GAMMA Investing LLC Purchases 814,713 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 89,825.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 815,620 shares of the biopharmaceutical company's stock after purchasing an additional 814,713 shares during the quarter. GAMMA Investing LLC owned 0.75% of Regeneron Pharmaceuticals worth $517,291,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of REGN. Pamalican Asset Management Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $356,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after acquiring an additional 4,457 shares during the period. Fagan Associates Inc. grew its position in shares of Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners grew its position in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 1,272 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of Regeneron Pharmaceuticals stock traded up $6.73 on Wednesday, reaching $494.59. The company had a trading volume of 832,764 shares, compared to its average volume of 844,650. The firm has a market cap of $53.40 billion, a price-to-earnings ratio of 12.92, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm's 50-day moving average price is $578.30 and its two-hundred day moving average price is $662.58. Regeneron Pharmaceuticals, Inc. has a 1 year low of $481.58 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on REGN shares. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. UBS Group cut their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday. Finally, Citigroup cut their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $847.40.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.